Fructosamine Is a Useful Indicator of Hyperglycaemia and Glucose Control in Clinical and Epidemiological Studies – Cross-Sectional and Longitudinal Experience from the AMORIS Cohort

Fructosamine is a glycemic biomarker which may be useful for indication and control of diabetes respectively. The objective of the study was to evaluate fructosamine as an indicator of hyperglycaemia and glucose control in subjects with diabetes. From the AMORIS cohort, subjects with serum glucose,...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 9; no. 10; p. e111463
Main Authors Malmström, Håkan, Walldius, Göran, Grill, Valdemar, Jungner, Ingmar, Gudbjörnsdottir, Soffia, Hammar, Niklas
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 29.10.2014
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Fructosamine is a glycemic biomarker which may be useful for indication and control of diabetes respectively. The objective of the study was to evaluate fructosamine as an indicator of hyperglycaemia and glucose control in subjects with diabetes. From the AMORIS cohort, subjects with serum glucose, fructosamine and HbA1c from the same examination were studied cross-sectionally and longitudinally (n = 10,987; 5,590 overnight-fasting). The guidelines of the American Diabetes Association were followed for classification of prediabetes and diabetes. Separate analyses were performed in patients with a newly detected or a known diagnosis of type 1 or type 2 diabetes respectively. All three biomarkers were strongly correlated. With regard to the association between fructosamine and HbA1c Pearson linear correlation coefficients in the range of 0.67-0.75 were observed in fasting and non-fasting subjects with type 1 or type 2 diabetes. Analyses of glucose control in fasting patients with type 2 diabetes having all three biomarkers measured at three separate occasions within on average 290 days of the index examination showed similar trends over time for glucose, fructosamine and HbA1c. Discrimination of subjects with and without diabetes across the range of fructosamine levels was good (area under curve (AUC) 0.91-0.95) and a fructosamine level of 2.5 mmol/L classified subjects to diabetes with a sensitivity of 61% and a specificity of 97%. Fructosamine is closely associated with HbA1c and glucose respectively and may be a useful biomarker of hyperglycaemia and glucose control in clinical and epidemiological studies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
Competing Interests: Niklas Hammar is an adjunct professor of epidemiology at the Institute of Environmental Medicine, Karolinska Institutet (KI) and also employee of AstraZeneca Research & Development, Mölndal, Sweden. The research of the current study has no relation to the drug development or other activities performed by AstraZeneca and AstraZeneca had no influence on the initiation, conduct or interpretation of the study. The CALAB laboratory was overtaken by another company in 1997 but the laboratory database containing data from 1985 to 1996 was still owned and managed by Ingmar Jungner. Jungner donated the database to the Institute of Environmental Medicine in 2012. Ingmar Jungner is retired since many years and is not active in any business activities. He still is a member of the AMORIS Steering Committee. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Conceived and designed the experiments: HM GW NH. Analyzed the data: HM. Contributed reagents/materials/analysis tools: IJ. Contributed to the writing of the manuscript: HM GW NH VG SG.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0111463